Paragangliomas da Cabeça e Pescoço: A Experiência de um Centro Oncológico do Sul da Europa

Authors

  • Luís Castelhano Serviço de Otorrinolaringologia. Hospital de Egas Moniz. Centro Hospitalar Lisboa Ocidental. Lisboa. https://orcid.org/0000-0001-6501-6941
  • Filipe Correia Serviço de Otorrinolaringologia. Hospital de Egas Moniz. Centro Hospitalar Lisboa Ocidental. Lisboa. https://orcid.org/0000-0002-5092-5621
  • Sara Donato Serviço de Endocrinologia. Instituto Português de Oncologia Francisco Gentil. Lisboa. https://orcid.org/0000-0001-8704-5292
  • Lígia Ferreira Serviço de Otorrinolaringologia. Instituto Português de Oncologia Francisco Gentil. Lisboa. https://orcid.org/0000-0001-7268-7495
  • Pedro Montalvão Serviço de Otorrinolaringologia. Instituto Português de Oncologia Francisco Gentil. Lisboa.
  • Miguel Magalhães Serviço de Otorrinolaringologia. Instituto Português de Oncologia Francisco Gentil. Lisboa.

DOI:

https://doi.org/10.20344/amp.17185

Keywords:

Carotid Body Tumor, Cranial Nerve Neoplasms, Extra-Adrenal Paraganglioma, Head and Neck Neoplasms, Paraganglioma

Abstract

Introduction: Paragangliomas are usually benign slow-growing tumors, but they are locally invasive and can cause significant morbidity. The aim of this study was to characterize the presenting symptoms, secretory status, genetics, imaging features, treatment modalities, post-treatment complications and survival of patients with head and neck paragangliomas treated at a single institution.
Material and Methods: We retrospectively reviewed the clinical records of patients managed at our center between 1997 and 2020.
Results: Seventy-three patients were included in the study, encompassing 89 head and neck paragangliomas. Forty-eight patients (65.8%) were female and 15 (20.5%) had multiple tumor sites (including 10 patients with multicentric benign paragangliomas and five with disseminated malignant disease). Regarding location, our series encompassed 40 temporal bone paragangliomas (44.9%), 24 carotid body paragangliomas (27%), 22 vagal paragangliomas (24.7%), two laryngeal paragangliomas (2.2%) and one sinonasal paraganglioma (1.1%). Excessive catecholamine secretion was detected in 11 patients (15.1%). Sixty-four patients (87.7%) underwent genetic testing. Of those, 24 (37.5%) exhibited pathogenic succinate dehydrogenase complex germline mutations. Regarding patients who presented with untreated disease, 45 patients (66.2%), encompassing 55 tumors, underwent surgery as primary treatment modality, 20 (29.4%; 23 tumors) were initially treated with radiotherapy and three patients (4.4%, encompassing three solitary tumors) were kept solely under watchful waiting. Five-year overall survival was 94.9% and disease-free survival was 31.9%.
Conclusion: Head and neck paragangliomas are rare, slow-growing but locally aggressive tumors resulting in high morbidity but low mortality rates.

Downloads

Download data is not yet available.

References

Sivalingam S, Shin SH, Lella FD, Lauda L, Sanna M. Tympanojugular paragangliomas. In: Kirtane MV, Souza CE, editors. Otology and

neurotology. Stuttgart: Thieme; 2013. Chapter 34.

Sanna M, Piazza P, Shin SH, Flanagan S, Mancini F. Microsurgery of skull base paragangliomas. Stuttgart: Thieme; 2013.

Prasad SC, Paties CT, Pantalone MR, Mariani-Constantini R, Sanna M. Carotid body and vagal paragangliomas: epidemiology, genetics, clinicopathological features, imaging, and surgical management. In: Mariani-Costantini R, editor. Paragangliomas: a multidisciplinary approach. Brisbane; Codon Publications; 2019. Chapter 5.

Prasad SC, Paties CT, Schiavi F, Esposito DL, Lotti LV, Mariani-Costantini R, et al. Tympanojugular paragangliomas: surgical

management and clinicopathological features. In: Mariani-Costantini R, editor. Paragangliomas: a multidisciplinary approach. Brisbane; Codon Publications; 2019. Chapter 6.

Lee JH, Barich F, Karnell LH, Robinson RA, Zhen WK, Gantz BJ, et al. National Cancer Data Base report on malignant paragangliomas of the head and neck. Cancer. 2002;94:730-7.

Badenhop RF, Jansen JC, Fagan PA, Lord RS, Wang ZG, Foster WJ, et al. The prevalence of SDHB, SDHC, and SDHD mutations in patients with head and neck paraganglioma and association of mutations with clinical features. J Med Genet. 2004;41:e99.

Baysal BE. Hereditary paraganglioma targets diverse paraganglia. J Med Genet 2002;39:617–22.

Williams MD. Paragangliomas of the head and neck: an overview from diagnosis to genetics. Head Neck Pathol. 2017;11:278-87.

Martins R, Bugalho MJ. Paragangliomas/pheochromocytomas: clinically oriented genetic testing. Int J Endocrinol. 2014;2014:794187.

Gupta N, Strome SE, Hatten KM. Is routine genetic testing warranted in head and neck paragangliomas? Laryngoscope. 2019;129:1491-3.

Majewska A, Budny B, Ziemnicka K, Ruchała M, Wierzbicka M. Head and neck paragangliomas - a genetic overview. Int J Mol Sci. 2020;21:7669.

Valero C, Ganly I, Shah JP. Head and neck paragangliomas: 30-year experience. Head Neck. 2020;42:2486-95.

González-Orús Álvarez-Morujo RJ, Arístegui Ruiz MÁ, da Costa Belisario J, Martinez Guirado T, Scola Yurrita B. Head and neck paragangliomas: experience in 126 patients with 162 tumours. Acta Otorrinolaringol Esp. 2015;66:332-41.

Moore MG, Netterville JL, Mendenhall WM, Isaacson B, Nussenbaum B. Head and neck paragangliomas: an update on evaluation and Mmanagement. Otolaryngol Head Neck Surg. 2016;154:597-605.

Sanna M, Fois P, Pasanisi E, Russo A, Bacciu A. Middle ear and mastoid glomus tumors (glomus tympanicum): an algorithm for the surgical management. Auris Nasus Larynx. 2010;37:661-8.

Luna-Ortiz K, Rascon-Ortiz M, Villavicencio-Valencia V, Herrera-Gomez A. Does Shamblin’s classification predict postoperative morbidity in carotid body tumors? A proposal to modify Shamblin’s classification. Eur Arch Otorhinolaryngol. 2006;263:171-5. Erratum in: Eur Arch Otorhinolaryngol. 2006;263:1161.

Netterville JL, Jackson CG, Miller FR, Wanamaker JR, Glasscock ME. Vagal paraganglioma: a review of 46 patients treated during a 20-year period. Arch Otolaryngol Head Neck Surg. 1998;124:1133-40.

House JW, Brackmann DE. Facial nerve grading system. Otolaryngol Head Neck Surg. 1985;93:146-7.

Cass ND, Schopper MA, Lubin JA, Fishbein L, Gubbels SP. The changing paradigm of head and neck paragangliomas: what every Otolaryngologist needs to know. Ann Otol Rhinol Laryngol. 2020;129:1135-43.

Erickson D, Kudva YC, Ebersold MJ, Thompson GB, Grant CS, van Heerden JA, et al. Benign paragangliomas: clinical presentation

and treatment outcomes in 236 patients. J Clin Endocrinol Metab. 2001;86:5210-6.

Liu P, Li M, Guan X, Yu A, Xiao Q, Wang C, et al. Clinical syndromes and genetic screening strategies of pheochromocytoma and paraganglioma. J Kidney Cancer VHL. 2018;5:14-22.

Opocher G, Schiavi F. Genetics of pheochromocytomas and paragangliomas. Best Pract Res Clin Endocrinol Metab. 2010;24:943-

Lenders JW, Kerstens MN, Amar L, Prejbisz A, Robledo M, Taieb D, et al. Genetics, diagnosis, management and future directions of research of phaeochromocytoma and paraganglioma: a position statement and consensus of the Working Group on Endocrine Hypertension of the European Society of Hypertension. J Hypertens. 2020;38:1443-56.

Álvarez-Morujo RJ, Ruiz MÁ, Serafini DP, Delgado IL, Friedlander E, Yurrita BS. Management of multicentric paragangliomas: review of 24 patients with 60 tumors. Head Neck. 2016;38:267-76.

Rijken JA, de Vos B, van Hest LP, Dreijerink KM, den Heijer M, Wisselink W, et al. Evolving management strategies in head and neck

paragangliomas: a single-centre experience with 147 patients over a 60-year period. Clin Otolaryngol. 2019;44:836-41.

Prasad SC, Sanna M. The role of radiation in tympanojugular paragangliomas needs to be objectively re-evaluated. Otol Neurotol.

;38:1060-2.

Wang J, Wakeman TP, Lathia JD, Hjelmeland AB, Wang XF, White RR, et al. Notch promotes radioresistance of glioma stem cells. Stem Cells. 2010;28:17–8.

Cama A, Verginelli F, Lotti LV, Napolitano F, Morgano A, D’Orazio A, et al. Integrative genetic, epigenetic and pathological analysis of

paraganglioma reveals complex dysregulation of NOTCH signaling. Acta Neuropathol. 2013;126:575–94.

Lin J, Liu C, Gao F, Mitchel RE, Zhao L, Yang Y, et al. miR-200c enhances radiosensitivity of human breast cancer cells. J Cellular

Biochem. 2013;114:606-15.

Metheetrairut C, Slack FJ. MicroRNAs in the ionizing radiation response and in radiotherapy. Curr Opin Genet Dev. 2013;23:12–9.

Maki Y, Asano H, Toyooka S, Soh J, Kubo T, Katsui K, et al. MicroRNA miR-34b/c enhances cellular radiosensitivity of malignant pleural mesothelioma cells. Anticancer Res. 2012;32:4871–5.

Sen C, Hague K, Kacchara R, Jenkins A, Das S, Catalano P. Jugular foramen: microscopic anatomic features and implications for neural preservation with reference to glomus tumors involving the temporal bone. Neurosurgery. 2001;48:838–47. discussion 847 – 8.

Spector GJ, Fierstein J, Ogura JH. A comparison of therapeutic modalities of glomus tumors in the temporal bone. Laryngoscope.

;86:690–6.

Handel SF, Miller MH, Miller LS, Goepfert H, Wallace S. Angiographic changes of head and neck chemodectomas following radiotherapy. Arch Otolaryngol. 1977;103:87–9.

Downloads

Published

2022-03-15

How to Cite

1.
Castelhano L, Correia F, Donato S, Ferreira L, Montalvão P, Magalhães M. Paragangliomas da Cabeça e Pescoço: A Experiência de um Centro Oncológico do Sul da Europa. Acta Med Port [Internet]. 2022 Mar. 15 [cited 2022 Dec. 7];35(11):789-97. Available from: https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/17185

Issue

Section

Original